A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | MicrobiomeTrials
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-04-24Est. Completion: 2028-03
Enrollment target: 390 participants
Locations
City of Hope National Medical Center /ID# 270255, Duarte, California, United States
UCLA - Santa Monica /ID# 270621, Santa Monica, California, United States
Yale New Haven Hospital /ID# 270565, New Haven, Connecticut, United States
University of Chicago Medical Center /ID# 271688, Chicago, Illinois, United States
Hope And Healing Cancer Services /ID# 271562, Hinsdale, Illinois, United States
Dana-Farber Cancer Institute /ID# 270624, Boston, Massachusetts, United States
Saint Lukes Hospital of Kansas City /ID# 270633, Kansas City, Missouri, United States
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646, Omaha, Nebraska, United States
University of North Carolina Medical Center /ID# 267786, Chapel Hill, North Carolina, United States
Oncology Hematology Care - Eastgate /ID# 271493, Cincinnati, Ohio, United States
Texas Oncology - Austin Midtown /ID# 271354, Austin, Texas, United States
Texas Oncology - Deke Slayton Cancer Center /ID# 271355, Webster, Texas, United States
Virginia Cancer Specialists - Fairfax /ID# 271351, Fairfax, Virginia, United States
Macquarie University /ID# 271514, Sydney, New South Wales, Australia
Other microbiome trials you might be interested in